Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

1. A solid form of Compound 1:

characterized by an X-ray Powder Diffraction (XRPD) pattern with a peak at angle (2 theta±0.2) of 6.3.

2. The solid form of claim 1 , wherein the XRPD pattern further comprises a peak at angle (2 theta±0.2) of 5.7.

3. The solid form of claim 1 characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event observed at about 256.6° C.

4. An oral unit dosage form comprising, a solid form of (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, wherein the solid form is characterized by an X-ray Powder Diffraction (XRPD) pattern with a peak at angle (2 theta±0.2) of 6.3, and

one or more excipients selected from the group consisting of a filler, a disintegrant, a lubricant, and a glidant.

5. The oral unit dosage form of claim 4 , comprising a total of about 50-150 mg of the ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.

6. The oral unit dosage form of claim 4 , comprising a total of about 150 mg of the ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.

7. The oral unit dosage form of claim 4 , comprising a filler wherein the filler comprises microcrystalline cellulose.

8. The oral unit dosage form of claim 4 , comprising a disintegrant, wherein the disintegrant comprises croscarmellose sodium.

9. The oral dosage unit of claim 4 , comprising a glidant, wherein the glidant comprises colloidal silicon dioxide.

10. The oral dosage unit of claim 4 , further comprising a lubricant.

11. The oral dosage unit of claim 10 , wherein the lubricant comprises magnesium stearate.

12. The oral dosage unit of claim 4 , wherein the (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile is about 33 percent by weight of the oral dosage unit.

13. The oral dosage unit of claim 10 , wherein the (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, the filler, the disintegrant and the lubricant are present in a relative weight ratio of about 33:61:5:1.